AR127783A1 - Composición farmacéutica que comprende compuestos de drogas biofarmacéuticas - Google Patents
Composición farmacéutica que comprende compuestos de drogas biofarmacéuticasInfo
- Publication number
- AR127783A1 AR127783A1 ARP220103247A ARP220103247A AR127783A1 AR 127783 A1 AR127783 A1 AR 127783A1 AR P220103247 A ARP220103247 A AR P220103247A AR P220103247 A ARP220103247 A AR P220103247A AR 127783 A1 AR127783 A1 AR 127783A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- combination
- carrier material
- compositions
- Prior art date
Links
- 229960000074 biopharmaceutical Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- -1 alkyl saccharides Chemical class 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- 229920001353 Dextrin Polymers 0.000 abstract 1
- 239000004375 Dextrin Substances 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229920002774 Maltodextrin Polymers 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 239000012876 carrier material Substances 0.000 abstract 1
- 235000019425 dextrin Nutrition 0.000 abstract 1
- 150000002016 disaccharides Chemical class 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
- 229940032085 sucrose monolaurate Drugs 0.000 abstract 1
- 150000003445 sucroses Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0043—Non-destructive separation of the package, e.g. peeling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0061—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using pre-packed dosages having an insert inside
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/07—General characteristics of the apparatus having air pumping means
- A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
- A61M2205/073—Syringe, piston type
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Fire-Extinguishing By Fire Departments, And Fire-Extinguishing Equipment And Control Thereof (AREA)
Abstract
De acuerdo con la invención se proporciona una composición que está en forma de un polvo monoparticulado amorfo que comprende una mezcla de: (a) una dosis farmacológicamente eficaz de al menos un compuesto biofarmacéutico; y (b) un material portador aceptable desde el punto de vista farmacéutico, dicho material portador comprende una combinación de un disacárido y un material polimérico. Los portadores aceptables desde el punto de vista farmacéutico preferidos a este respecto incluyen lactosa o trehalosa y dextrinas (por ejemplo, maltodextrinas). Las composiciones pueden comprender además uno o más sacáridos de alquilo. Los sacáridos de alquilo preferidos incluyen ésteres de sacarosa, tales como monolaurato de sacarosa. Las composiciones en polvo se pueden producir mediante el secado por pulverización de los diversos componentes en combinación.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2117005.5A GB202117005D0 (en) | 2021-11-25 | 2021-11-25 | New pharmaceutical composition |
| GBGB2208144.2A GB202208144D0 (en) | 2022-06-01 | 2022-06-01 | New pharmaceutical composition |
| GBGB2213306.0A GB202213306D0 (en) | 2022-09-12 | 2022-09-12 | New pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127783A1 true AR127783A1 (es) | 2024-02-28 |
Family
ID=84367624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103247A AR127783A1 (es) | 2021-11-25 | 2022-11-25 | Composición farmacéutica que comprende compuestos de drogas biofarmacéuticas |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4436551A1 (es) |
| KR (1) | KR20240111761A (es) |
| AR (1) | AR127783A1 (es) |
| AU (1) | AU2022398370A1 (es) |
| CA (1) | CA3239053A1 (es) |
| IL (1) | IL313015A (es) |
| MX (1) | MX2024006130A (es) |
| TW (1) | TW202329916A (es) |
| WO (1) | WO2023094818A1 (es) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19518810A1 (de) | 1995-05-26 | 1996-11-28 | Bayer Ag | Nasal-Applikator |
| US6398074B1 (en) | 1998-03-10 | 2002-06-04 | Valois S.A. | Reservoir, reservoir filling method and device for dispensing fluid contained in the reservoir |
| FR2817847B1 (fr) | 2000-12-08 | 2003-03-28 | Tebro | Dispositif de distribution de produit fluide ou pulverulent |
| LU90825B1 (en) | 2001-09-06 | 2003-03-07 | Iee Sarl | Method for the determination of one or more parameters of a seat passenger |
| CA2540204A1 (en) | 2003-10-09 | 2005-04-21 | Bioactis Limited | Device to deliver powdery medicine into nasal cavity |
| NZ601913A (en) * | 2008-01-15 | 2014-02-28 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
| EP2266563A1 (en) | 2009-06-11 | 2010-12-29 | Charité-Universitätsmedizin Berlin (Charité) | Use of opioid receptor antagonists for acute treatment of paraphilic arousal states |
| US8827946B2 (en) | 2009-07-31 | 2014-09-09 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal granisetron and nasal applicator |
| JP5623355B2 (ja) | 2010-07-30 | 2014-11-12 | オートリブ ディベロップメント エービー | カーテンエアバッグ |
| EP2866867B1 (en) | 2012-06-28 | 2017-05-31 | The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services | Nasal dry powder delivery system for vaccines and other treatment agents |
| FR3007992B1 (fr) | 2013-07-05 | 2018-01-26 | Aptar France Sas | Dispositif de distribution de produit fluide ou pulverulent. |
| CN104489669A (zh) * | 2014-12-12 | 2015-04-08 | 深圳先进技术研究院 | 一种植物酵素益生菌粉及其制备方法 |
| AU2018319592B2 (en) | 2017-08-20 | 2024-06-27 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| EP3698773A1 (en) * | 2019-02-21 | 2020-08-26 | Università degli Studi di Parma | Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination |
| US10653690B1 (en) | 2019-07-09 | 2020-05-19 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| FR3098420B1 (fr) | 2019-07-10 | 2021-07-09 | Aptar France Sas | Dispositif de distribution nasale de poudre |
| ES2929818T3 (es) * | 2020-05-18 | 2022-12-02 | Orexo Ab | Nueva composición farmacéutica para la administración de fármacos |
| FR3121047B1 (fr) | 2021-03-29 | 2023-07-14 | Aptar France Sas | Dispositif de distribution nasale de poudre |
-
2022
- 2022-11-25 AU AU2022398370A patent/AU2022398370A1/en active Pending
- 2022-11-25 TW TW111145223A patent/TW202329916A/zh unknown
- 2022-11-25 AR ARP220103247A patent/AR127783A1/es unknown
- 2022-11-25 WO PCT/GB2022/052985 patent/WO2023094818A1/en active Application Filing
- 2022-11-25 IL IL313015A patent/IL313015A/en unknown
- 2022-11-25 EP EP22814493.7A patent/EP4436551A1/en active Pending
- 2022-11-25 CA CA3239053A patent/CA3239053A1/en active Pending
- 2022-11-25 KR KR1020247018845A patent/KR20240111761A/ko unknown
- 2022-11-25 MX MX2024006130A patent/MX2024006130A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022398370A1 (en) | 2024-05-30 |
| WO2023094818A1 (en) | 2023-06-01 |
| MX2024006130A (es) | 2024-06-04 |
| CA3239053A1 (en) | 2023-06-01 |
| IL313015A (en) | 2024-07-01 |
| KR20240111761A (ko) | 2024-07-17 |
| EP4436551A1 (en) | 2024-10-02 |
| TW202329916A (zh) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022000254A2 (es) | Composición farmacéutica para suministro nasal | |
| CL2022002979A1 (es) | Nueva composición farmacéutica para administración de fármacos | |
| SV2018005742A (es) | Inhibidores de mcl-1 macrocíclicos para tratar el cáncer | |
| AR112392A1 (es) | Compuesto tricíclico de pirazol, su uso para fabricar un medicamento y composición farmaceutica que lo comprende | |
| CO2022005128A2 (es) | Profármacos antivirales y formulaciones de los mismos | |
| AR053162A1 (es) | Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma. | |
| AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
| PH12018501077A1 (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
| RU2017117559A (ru) | Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение | |
| AR085549A1 (es) | DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
| CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
| AR082444A1 (es) | Formulacion farmaceutica que comprende un inhibidor de fosfodiesterasa | |
| MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
| AR087470A1 (es) | Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen | |
| PE20081113A1 (es) | Inhibidores virales policiclicos | |
| AR100440A1 (es) | Derivados de carboxamida como inhibidores selectivos de smurf1 | |
| PE20080342A1 (es) | Inhibidores de proteasa de hiv de 2-(amino-sustituido)-benzotiazol sulfonamida | |
| AR127470A1 (es) | Inhibidores de lrrk2 | |
| PE20061418A1 (es) | Composiciones farmaceuticas de 4-[(ciclopropanocarbonilamino)metil]-2-(2,6-dioxopiperidin-3-il)isoindol-1,3-diona para el tratamiento o prevencion de lupus cutaneo | |
| CL2022001323A1 (es) | Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x | |
| AR128931A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| AR127783A1 (es) | Composición farmacéutica que comprende compuestos de drogas biofarmacéuticas | |
| PE20211454A1 (es) | Derivados de imidazopiridina y su uso como medicamento | |
| AR119317A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 |